- Home
- PROK vs UNCY Comparison
PROK vs UNCY Comparison
Compare PROK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- UNCY
- Stock Information
- Founded
- PROK 2015
- UNCY 2016
- Country
- PROK United States
- UNCY United States
- Employees
- PROK N/A
- UNCY N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- PROK Health Care
- UNCY Health Care
- Exchange
- PROK Nasdaq
- UNCY Nasdaq
- Market Cap
- PROK 85.5M
- UNCY 91.0M
- IPO Year
- PROK N/A
- UNCY 2021
- Fundamental
- Price
- PROK $4.74
- UNCY $4.95
- Analyst Decision
- PROK Buy
- UNCY Strong Buy
- Analyst Count
- PROK 4
- UNCY 4
- Target Price
- PROK $5.33
- UNCY $63.75
- AVG Volume (30 Days)
- PROK 33.1M
- UNCY 1.2M
- Earning Date
- PROK 08-08-2025
- UNCY 08-13-2025
- Dividend Yield
- PROK N/A
- UNCY N/A
- EPS Growth
- PROK N/A
- UNCY N/A
- EPS
- PROK N/A
- UNCY N/A
- Revenue
- PROK $306,000.00
- UNCY N/A
- Revenue This Year
- PROK $54.34
- UNCY N/A
- Revenue Next Year
- PROK N/A
- UNCY $1,458.53
- P/E Ratio
- PROK N/A
- UNCY N/A
- Revenue Growth
- PROK N/A
- UNCY N/A
- 52 Week Low
- PROK $0.46
- UNCY $2.02
- 52 Week High
- PROK $7.13
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- PROK 92.14
- UNCY 43.02
- Support Level
- PROK $0.54
- UNCY $4.31
- Resistance Level
- PROK $7.13
- UNCY $5.55
- Average True Range (ATR)
- PROK 0.62
- UNCY 0.76
- MACD
- PROK 0.47
- UNCY -0.10
- Stochastic Oscillator
- PROK 68.59
- UNCY 16.26
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.